MENLO PARK, Calif.--(BUSINESS WIRE)--Today xCella Biosciences announced a new antibody discovery research collaboration with Teva Pharmaceuticals Australia Pty Ltd. xCella will use its xPlorationTM single cell screening platform to identify rare antibodies against an undisclosed target of interest to Teva.
“Our xPloration platform offers new technology for high-throughput B cell screening to enable antibody discovery against complex membrane protein targets. We look forward to working closely with Teva, a leading global company, to help them achieve their drug discovery goals.” said Dr. Jennifer Cochran, Co-Founder and Executive Chairman of xCella.
“Teva is excited to utilize xCella’s xPloration platform and expertise to identify unique antibodies against our therapeutic targets,” said Dr. Steffen Nock, Senior Vice President, Global Specialty R&D at Teva.
Under the terms of this agreement, xCella Biosciences will receive certain payments based on the development and commercialization of therapeutic antibodies for up to four disease targets. Specific financial terms of the agreement have not been disclosed.
About xCella Biosciences
xCella is an antibody engineering and drug discovery company based on intellectual property originally developed at Stanford University in the Stanford Photonics Research Center and the laboratory of Dr. Jennifer Cochran in the Stanford Department of Bioengineering. The xPlorationTM platform enables high throughput screening of millions of B cells based on cell binding or functional activity, presenting distinctive opportunities for the creation of novel therapeutics. In addition to its internal drug discovery and development programs, xCella has entered into partnership agreements with leading pharmaceutical and biotechnology companies to develop best in-class protein-based assets in key strategic areas of interest.
Teva Pharmaceutical Industries Ltd. has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 35,000 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com